Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts
Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetyla...
Gespeichert in:
| Veröffentlicht in: | PloS one 2019-12, Vol.14 (12), p.e0227098-e0227098 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0227098 |
|---|---|
| container_issue | 12 |
| container_start_page | e0227098 |
| container_title | PloS one |
| container_volume | 14 |
| creator | Ganan, Monica Lorentzen, Silje B Aam, Berit B Eijsink, Vincent G H Gaustad, Peter Sørlie, Morten |
| description | Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetylation (FA) of 0.15 against medically relevant yeast strains was studied. The minimal inhibitory concentration (MIC) of C32 varied greatly among strains, ranging from > 5000 μg mL-1 (Candida albicans and C. glabrata) to < 4.9 (C. tropicalis). A synergistic effect was observed between C32 and the different antifungals tested for most of the strains. Testing of several CHOS preparations indicated that the highest synergistic effects are obtained for fractions with a DPn in the 30-50 range. Pre-exposure to C32 enhanced the antifungal effect of fluconazole and amphotericin B. A concentration-dependent post-antifungal effect conserved even 24 h after C32 removal was observed. The combination of C32 and commercial antifungals together or as part of a sequential therapy opens new therapeutic perspectives for treating yeast infections in humans. |
| doi_str_mv | 10.1371/journal.pone.0227098 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2331618694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A610169890</galeid><doaj_id>oai_doaj_org_article_8e3d53a9d0a64695aa26553e9a32a0ba</doaj_id><sourcerecordid>A610169890</sourcerecordid><originalsourceid>FETCH-LOGICAL-c646t-76ace10fc3bcd232d4a95a8b5bd0de79ed2debe6fc93a05375d01b7fde5099933</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEoqXwBggiISG42MWON058g1RVHCpVqsTp1prYk6wrr721nZbl5Xg1nHZbuqgXKBeOPd8c_I-nKJ5TMqesoe_O_Bgc2PnaO5yTqmqIaB8U-1SwasYrwh7e-d8rnsR4RkjNWs4fF3uMtoJyKvaL34cumc74ZFQZ4cK4ocS-R5VK35fKrzrjIBnvyrTEAOtNXoMfh2UZNw7DYOLkaFzKRjVxsewwXSK68hKtnaklTAYM5hfqUi1N8jNvzeAjqMlmNMYSnJ5SrTAoAzZvk-lHN4DNpgGMi6lcoTYKrN2UAS1eZKTcIMQUnxaP-gzis-16UHz_-OHb0efZyemn46PDk5niC55mDQeFlPSKdUpXrNILEDW0Xd1porERqCuNHfJeCQZZpqbWhHZNr7EmQgjGDoqX13HX1ke51T7KirGsY8vFIhPH14T2cCbXwawgbKQHI68OfBgkhKyWRdki0zUDoQnk6nIhUPG6ZiiAVUA6yLHeb7ONXb66QpcC2J2guxZnlnLwF5IL1jJK_parwtQiJ50PIClp60o2nC7aTLzZpgj-fMSY5MpElXsGDv14fbNGCE5pRl_9g95__y2VG4fSuN7nytQUVB5ySigXrZgKm99D5U_jyqj8lHuTz3cc3u44ZCbhzzTAGKM8_vrl_9nTH7vs6zvsEsGmZfR2vHrEu-DiRkofY8D-tg2UyGkSb9SQ0yTK7SRmtxd3W3jrdDN67A9_hTRC</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331618694</pqid></control><display><type>article</type><title>Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ganan, Monica ; Lorentzen, Silje B ; Aam, Berit B ; Eijsink, Vincent G H ; Gaustad, Peter ; Sørlie, Morten</creator><contributor>Wang, Qian</contributor><creatorcontrib>Ganan, Monica ; Lorentzen, Silje B ; Aam, Berit B ; Eijsink, Vincent G H ; Gaustad, Peter ; Sørlie, Morten ; Wang, Qian</creatorcontrib><description>Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetylation (FA) of 0.15 against medically relevant yeast strains was studied. The minimal inhibitory concentration (MIC) of C32 varied greatly among strains, ranging from > 5000 μg mL-1 (Candida albicans and C. glabrata) to < 4.9 (C. tropicalis). A synergistic effect was observed between C32 and the different antifungals tested for most of the strains. Testing of several CHOS preparations indicated that the highest synergistic effects are obtained for fractions with a DPn in the 30-50 range. Pre-exposure to C32 enhanced the antifungal effect of fluconazole and amphotericin B. A concentration-dependent post-antifungal effect conserved even 24 h after C32 removal was observed. The combination of C32 and commercial antifungals together or as part of a sequential therapy opens new therapeutic perspectives for treating yeast infections in humans.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0227098</identifier><identifier>PMID: 31891619</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acetylation ; Amphotericin B ; Amphotericin B - pharmacology ; Amphotericin B - therapeutic use ; Antibiotics ; Antifungal activity ; Antifungal agents ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; Antimicrobial agents ; Antiparasitic agents ; Biology and Life Sciences ; Biotechnology ; Candida - drug effects ; Candida - isolation & purification ; Candidiasis ; Candidiasis - drug therapy ; Candidiasis - microbiology ; Chemistry ; Chitosan ; Chitosan - chemistry ; Chitosan - pharmacology ; Chitosan - therapeutic use ; Chromatography ; Clinical medicine ; Combination therapy ; Drug Resistance, Fungal - drug effects ; Drug Synergism ; Drug Therapy, Combination ; Fluconazole ; Fluconazole - pharmacology ; Fluconazole - therapeutic use ; Food science ; Fungal infections ; Fungicides ; Hemodialysis ; Humans ; Life sciences ; Low molecular weights ; Medicine and Health Sciences ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Molecular weight ; Oligosaccharides ; Physical Sciences ; Polymerization ; Polymers ; Proton Magnetic Resonance Spectroscopy ; Research and Analysis Methods ; Synergistic effect ; Synergistic effects ; Therapy ; Yeast ; Yeasts</subject><ispartof>PloS one, 2019-12, Vol.14 (12), p.e0227098-e0227098</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Ganan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>info:eu-repo/semantics/openAccess</rights><rights>2019 Ganan et al 2019 Ganan et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c646t-76ace10fc3bcd232d4a95a8b5bd0de79ed2debe6fc93a05375d01b7fde5099933</citedby><cites>FETCH-LOGICAL-c646t-76ace10fc3bcd232d4a95a8b5bd0de79ed2debe6fc93a05375d01b7fde5099933</cites><orcidid>0000-0001-7259-6710 ; 0000-0001-7277-0029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938310/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938310/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,26567,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31891619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Wang, Qian</contributor><creatorcontrib>Ganan, Monica</creatorcontrib><creatorcontrib>Lorentzen, Silje B</creatorcontrib><creatorcontrib>Aam, Berit B</creatorcontrib><creatorcontrib>Eijsink, Vincent G H</creatorcontrib><creatorcontrib>Gaustad, Peter</creatorcontrib><creatorcontrib>Sørlie, Morten</creatorcontrib><title>Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetylation (FA) of 0.15 against medically relevant yeast strains was studied. The minimal inhibitory concentration (MIC) of C32 varied greatly among strains, ranging from > 5000 μg mL-1 (Candida albicans and C. glabrata) to < 4.9 (C. tropicalis). A synergistic effect was observed between C32 and the different antifungals tested for most of the strains. Testing of several CHOS preparations indicated that the highest synergistic effects are obtained for fractions with a DPn in the 30-50 range. Pre-exposure to C32 enhanced the antifungal effect of fluconazole and amphotericin B. A concentration-dependent post-antifungal effect conserved even 24 h after C32 removal was observed. The combination of C32 and commercial antifungals together or as part of a sequential therapy opens new therapeutic perspectives for treating yeast infections in humans.</description><subject>Acetylation</subject><subject>Amphotericin B</subject><subject>Amphotericin B - pharmacology</subject><subject>Amphotericin B - therapeutic use</subject><subject>Antibiotics</subject><subject>Antifungal activity</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Antiparasitic agents</subject><subject>Biology and Life Sciences</subject><subject>Biotechnology</subject><subject>Candida - drug effects</subject><subject>Candida - isolation & purification</subject><subject>Candidiasis</subject><subject>Candidiasis - drug therapy</subject><subject>Candidiasis - microbiology</subject><subject>Chemistry</subject><subject>Chitosan</subject><subject>Chitosan - chemistry</subject><subject>Chitosan - pharmacology</subject><subject>Chitosan - therapeutic use</subject><subject>Chromatography</subject><subject>Clinical medicine</subject><subject>Combination therapy</subject><subject>Drug Resistance, Fungal - drug effects</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Fluconazole</subject><subject>Fluconazole - pharmacology</subject><subject>Fluconazole - therapeutic use</subject><subject>Food science</subject><subject>Fungal infections</subject><subject>Fungicides</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Life sciences</subject><subject>Low molecular weights</subject><subject>Medicine and Health Sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Molecular weight</subject><subject>Oligosaccharides</subject><subject>Physical Sciences</subject><subject>Polymerization</subject><subject>Polymers</subject><subject>Proton Magnetic Resonance Spectroscopy</subject><subject>Research and Analysis Methods</subject><subject>Synergistic effect</subject><subject>Synergistic effects</subject><subject>Therapy</subject><subject>Yeast</subject><subject>Yeasts</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>3HK</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEoqXwBggiISG42MWON058g1RVHCpVqsTp1prYk6wrr721nZbl5Xg1nHZbuqgXKBeOPd8c_I-nKJ5TMqesoe_O_Bgc2PnaO5yTqmqIaB8U-1SwasYrwh7e-d8rnsR4RkjNWs4fF3uMtoJyKvaL34cumc74ZFQZ4cK4ocS-R5VK35fKrzrjIBnvyrTEAOtNXoMfh2UZNw7DYOLkaFzKRjVxsewwXSK68hKtnaklTAYM5hfqUi1N8jNvzeAjqMlmNMYSnJ5SrTAoAzZvk-lHN4DNpgGMi6lcoTYKrN2UAS1eZKTcIMQUnxaP-gzis-16UHz_-OHb0efZyemn46PDk5niC55mDQeFlPSKdUpXrNILEDW0Xd1porERqCuNHfJeCQZZpqbWhHZNr7EmQgjGDoqX13HX1ke51T7KirGsY8vFIhPH14T2cCbXwawgbKQHI68OfBgkhKyWRdki0zUDoQnk6nIhUPG6ZiiAVUA6yLHeb7ONXb66QpcC2J2guxZnlnLwF5IL1jJK_parwtQiJ50PIClp60o2nC7aTLzZpgj-fMSY5MpElXsGDv14fbNGCE5pRl_9g95__y2VG4fSuN7nytQUVB5ySigXrZgKm99D5U_jyqj8lHuTz3cc3u44ZCbhzzTAGKM8_vrl_9nTH7vs6zvsEsGmZfR2vHrEu-DiRkofY8D-tg2UyGkSb9SQ0yTK7SRmtxd3W3jrdDN67A9_hTRC</recordid><startdate>20191231</startdate><enddate>20191231</enddate><creator>Ganan, Monica</creator><creator>Lorentzen, Silje B</creator><creator>Aam, Berit B</creator><creator>Eijsink, Vincent G H</creator><creator>Gaustad, Peter</creator><creator>Sørlie, Morten</creator><general>Public Library of Science</general><general>PLOS</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>3HK</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7259-6710</orcidid><orcidid>https://orcid.org/0000-0001-7277-0029</orcidid></search><sort><creationdate>20191231</creationdate><title>Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts</title><author>Ganan, Monica ; Lorentzen, Silje B ; Aam, Berit B ; Eijsink, Vincent G H ; Gaustad, Peter ; Sørlie, Morten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c646t-76ace10fc3bcd232d4a95a8b5bd0de79ed2debe6fc93a05375d01b7fde5099933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetylation</topic><topic>Amphotericin B</topic><topic>Amphotericin B - pharmacology</topic><topic>Amphotericin B - therapeutic use</topic><topic>Antibiotics</topic><topic>Antifungal activity</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Antiparasitic agents</topic><topic>Biology and Life Sciences</topic><topic>Biotechnology</topic><topic>Candida - drug effects</topic><topic>Candida - isolation & purification</topic><topic>Candidiasis</topic><topic>Candidiasis - drug therapy</topic><topic>Candidiasis - microbiology</topic><topic>Chemistry</topic><topic>Chitosan</topic><topic>Chitosan - chemistry</topic><topic>Chitosan - pharmacology</topic><topic>Chitosan - therapeutic use</topic><topic>Chromatography</topic><topic>Clinical medicine</topic><topic>Combination therapy</topic><topic>Drug Resistance, Fungal - drug effects</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Fluconazole</topic><topic>Fluconazole - pharmacology</topic><topic>Fluconazole - therapeutic use</topic><topic>Food science</topic><topic>Fungal infections</topic><topic>Fungicides</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Life sciences</topic><topic>Low molecular weights</topic><topic>Medicine and Health Sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Molecular weight</topic><topic>Oligosaccharides</topic><topic>Physical Sciences</topic><topic>Polymerization</topic><topic>Polymers</topic><topic>Proton Magnetic Resonance Spectroscopy</topic><topic>Research and Analysis Methods</topic><topic>Synergistic effect</topic><topic>Synergistic effects</topic><topic>Therapy</topic><topic>Yeast</topic><topic>Yeasts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganan, Monica</creatorcontrib><creatorcontrib>Lorentzen, Silje B</creatorcontrib><creatorcontrib>Aam, Berit B</creatorcontrib><creatorcontrib>Eijsink, Vincent G H</creatorcontrib><creatorcontrib>Gaustad, Peter</creatorcontrib><creatorcontrib>Sørlie, Morten</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganan, Monica</au><au>Lorentzen, Silje B</au><au>Aam, Berit B</au><au>Eijsink, Vincent G H</au><au>Gaustad, Peter</au><au>Sørlie, Morten</au><au>Wang, Qian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-12-31</date><risdate>2019</risdate><volume>14</volume><issue>12</issue><spage>e0227098</spage><epage>e0227098</epage><pages>e0227098-e0227098</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetylation (FA) of 0.15 against medically relevant yeast strains was studied. The minimal inhibitory concentration (MIC) of C32 varied greatly among strains, ranging from > 5000 μg mL-1 (Candida albicans and C. glabrata) to < 4.9 (C. tropicalis). A synergistic effect was observed between C32 and the different antifungals tested for most of the strains. Testing of several CHOS preparations indicated that the highest synergistic effects are obtained for fractions with a DPn in the 30-50 range. Pre-exposure to C32 enhanced the antifungal effect of fluconazole and amphotericin B. A concentration-dependent post-antifungal effect conserved even 24 h after C32 removal was observed. The combination of C32 and commercial antifungals together or as part of a sequential therapy opens new therapeutic perspectives for treating yeast infections in humans.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31891619</pmid><doi>10.1371/journal.pone.0227098</doi><tpages>e0227098</tpages><orcidid>https://orcid.org/0000-0001-7259-6710</orcidid><orcidid>https://orcid.org/0000-0001-7277-0029</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2019-12, Vol.14 (12), p.e0227098-e0227098 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2331618694 |
| source | MEDLINE; NORA - Norwegian Open Research Archives; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acetylation Amphotericin B Amphotericin B - pharmacology Amphotericin B - therapeutic use Antibiotics Antifungal activity Antifungal agents Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Antimicrobial agents Antiparasitic agents Biology and Life Sciences Biotechnology Candida - drug effects Candida - isolation & purification Candidiasis Candidiasis - drug therapy Candidiasis - microbiology Chemistry Chitosan Chitosan - chemistry Chitosan - pharmacology Chitosan - therapeutic use Chromatography Clinical medicine Combination therapy Drug Resistance, Fungal - drug effects Drug Synergism Drug Therapy, Combination Fluconazole Fluconazole - pharmacology Fluconazole - therapeutic use Food science Fungal infections Fungicides Hemodialysis Humans Life sciences Low molecular weights Medicine and Health Sciences Microbial Sensitivity Tests Minimum inhibitory concentration Molecular weight Oligosaccharides Physical Sciences Polymerization Polymers Proton Magnetic Resonance Spectroscopy Research and Analysis Methods Synergistic effect Synergistic effects Therapy Yeast Yeasts |
| title | Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T17%3A05%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20saving%20effect%20of%20combination%20therapy%20through%20synergistic%20interactions%20between%20well-characterized%20chito-oligosaccharides%20and%20commercial%20antifungals%20against%20medically%20relevant%20yeasts&rft.jtitle=PloS%20one&rft.au=Ganan,%20Monica&rft.date=2019-12-31&rft.volume=14&rft.issue=12&rft.spage=e0227098&rft.epage=e0227098&rft.pages=e0227098-e0227098&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0227098&rft_dat=%3Cgale_plos_%3EA610169890%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2331618694&rft_id=info:pmid/31891619&rft_galeid=A610169890&rft_doaj_id=oai_doaj_org_article_8e3d53a9d0a64695aa26553e9a32a0ba&rfr_iscdi=true |